Erucic Acid
CAS 112-86-7
Erucic Acid (CAS 112-86-7) is a pharmaceutical compound with 4 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | GI50 | 34417.800689655174 nM | 58 | - |
| - | MIC | 391.1111111111111 ug.mL-1 | 9 | - |
| - | IC50 | 27142.85714285714 nM | 7 | - |
| - | Potency | 27127.140000000003 nM | 5 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Erucic Acid used for in pharmaceutical contexts?
Erucic Acid (CAS 112-86-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Erucic Acid?
No adverse-event association or SIDER side-effect rows are rendered for Erucic Acid in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Erucic Acid also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Erucic Acid with EU status "permitted".
What clinical phase is Erucic Acid in?
No phase 1-4 clinical development badge is rendered for Erucic Acid because the matched compound identifier rows do not contain a max-phase value.